Tartan LLC Profile last edited on: 10/1/2022
CAGE: 8JA35
UEI: DNKGD28FF8U3
Business Identifier: New therapeutic platforms 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 52
County: San Diego
Congr. District: 52
County: San Diego
Public Profile
Described only as in 'stealth mode", the only indicators of the firm's focusis reference in the STTR Abstract to development of a safe and effective treatment for a devastating form of pediatric epilepsy called Dravet syndrome
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2021 | 1 | NSF | $255,730 | |
| Project Title: Harnessing the power of introns for safe and effective therapeutics and genomic screening | ||||
Key People / Management
David A Nelles -- CEO, Co-founder, Chief Scientist
Company News
There are no news available.
